IFLR1000

Pfizer $17 billion acquisition of Hospira

3/9/2015
Public acquisition
Select tab

$ 17 billion

Completed

3/9/2015

Overview:

  • Pfizer has completed its $17 billion acquisition of Hospira.
  • The deal was first announced in February, 2015.
  • Pfizer paid $90 per Hospira share.
  • Ropes & Gray (Marko Zatylny, Paul Kinsella) and Clifford Chance advised Pfizer.
  • Skadden Arps Slate Meagher & Flom (Charles Mulaney Jr, Richard Witzel) advised Hospira.
  • Gibson Dunn & Crutcher (Eduardo Gallardo, Dennis Friedman) represented Pfizer financial advisers Lazard and Guggenheim Securities.
  • Davis Polk & Wardwell (Paul Kingsley, Scott Luftglass) represented Hospira financial adviser Morgan Stanley.

Kurt Stumpo - Journalist - North America and the Caribbean

Jurisdiction:

United States

Deal type:

Public acquisition

Practice area:

M&A

Governing law:

United States

Industry sector:

Pharmaceuticals and life sciences

Firms:
Clifford Chance

Party: Pfizer (Acquirer)

Davis Polk & Wardwell

Party: Morgan Stanley (Financial adviser)

Gibson Dunn & Crutcher

Party: Lazard (Financial adviser)

Party: Guggenheim Securities (Financial adviser)

Lawyer: Dennis Friedman

Ropes & Gray

Party: Pfizer (Acquirer)

Lawyer: Marko Zatylny

Skadden Arps Slate Meagher & Flom

Party: Hospira (Target)

Related deals